ArticleBreast cancer research and treatment2014

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.

Andrew R Green et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.